Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 109

1.

Psychiatric effects of ephedra use: an analysis of Food and Drug Administration reports of adverse events.

Maglione M, Miotto K, Iguchi M, Jungvig L, Morton SC, Shekelle PG.

Am J Psychiatry. 2005 Jan;162(1):189-91.

PMID:
15625222
2.

Psychiatric symptoms associated with ephedra use.

Maglione M, Miotto K, Iguchi M, Hilton L, Shekelle P.

Expert Opin Drug Saf. 2005 Sep;4(5):879-84. Review.

PMID:
16111450
3.
4.

Adverse events associated with supplements containing ephedra alkaloids.

Geiger JD.

Clin J Sport Med. 2002 Jul;12(4):263. No abstract available.

PMID:
12150162
5.

Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis.

Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, Rhodes SL, Jungvig L, Gagné J.

JAMA. 2003 Mar 26;289(12):1537-45. Epub 2003 Mar 10.

PMID:
12672771
6.

Seizures reported in association with use of dietary supplements.

Haller CA, Meier KH, Olson KR.

Clin Toxicol (Phila). 2005;43(1):23-30. Review.

PMID:
15732443
7.

Working to get ephedra banned.

[No authors listed]

Consum Rep. 2003 Feb;68(2):6. No abstract available.

PMID:
12516584
8.

FDA issues alert on ephedra supplements in the USA.

Nelson R.

Lancet. 2004 Jan 10;363(9403):135. No abstract available.

PMID:
14733193
9.

Addressing the potential risks associated with ephedra use: a review of recent efforts.

Schulman S.

Public Health Rep. 2003 Nov-Dec;118(6):487-92. Review.

10.

HHS to study ephedra, step up enforcement against illegal marketing.

[No authors listed]

FDA Consum. 2002 Sep-Oct;36(5):3. No abstract available.

11.

Ergogenic aids: an update on ephedra.

Keisler BD, Hosey RG.

Curr Sports Med Rep. 2005 Aug;4(4):231-5. Review.

PMID:
16004835
12.

Ephedra banned.

Cockey CD.

AWHONN Lifelines. 2004 Feb-Mar;8(1):19-25. No abstract available.

PMID:
15031882
13.

The need for regulation of dietary supplements--lessons from ephedra.

Fontanarosa PB, Rennie D, DeAngelis CD.

JAMA. 2003 Mar 26;289(12):1568-70. Epub 2003 Mar 10. No abstract available.

PMID:
12672775
14.

Coronary thrombosis related to use of Xenadrine RFA.

Sachdeva R, Sivasankaran S, Fishman RF, Zarich SW, McPherson CA.

Tex Heart Inst J. 2005;32(1):74-7.

15.

Cardiovascular effects of ephedra alkaloids: a comprehensive review.

Andraws R, Chawla P, Brown DL.

Prog Cardiovasc Dis. 2005 Jan-Feb;47(4):217-25. Review.

PMID:
15991150
16.

Banning ephedra: good call, poor vision.

Gordon JS.

Altern Ther Health Med. 2004 Nov-Dec;10(6):18-9. No abstract available.

PMID:
15624346
17.

FDA v. ephedra: is it time to lift the ban?

Pyle KR.

Food Drug Law J. 2006;61(4):701-51. No abstract available.

PMID:
17180770
18.

Medicine. Ephedra--scientific evidence versus money/politics.

Wolfe SM.

Science. 2003 Apr 18;300(5618):437. No abstract available. Erratum in: Science. 2003 May 21;300(5621):905.

PMID:
12702860
19.

Time to ban ephedra--now.

Guharoy R, Noviasky JA.

Am J Health Syst Pharm. 2003 Aug 1;60(15):1580-2. No abstract available.

PMID:
12951759
20.

Ocular side effects from herbal medicines and nutritional supplements.

Fraunfelder FW.

Am J Ophthalmol. 2004 Oct;138(4):639-47.

PMID:
15488795

Supplemental Content

Support Center